Clinical Trials Logo

Pediatric Cancer clinical trials

View clinical trials related to Pediatric Cancer.

Filter by:

NCT ID: NCT05923242 Completed - Pediatric Cancer Clinical Trials

Translating ECHOS2 Into an mHealth Platform

ECHOS2
Start date: July 5, 2023
Phase: N/A
Study type: Interventional

Childhood cancer survivors are at an increased risk of cardiac toxicity due to prior anti-cancer therapy. However, adherence to cardiac screening in this population remains low. This study aims to assess the feasibility of an mHealth motivational interviewing platform called Computerized Authoring Intervention Software (CIAS) in childhood cancer survivors. Participants will be recruited from the Childhood Cancer Survivorship Study.

NCT ID: NCT05918640 Recruiting - Pediatric Cancer Clinical Trials

Lurbinectedin in FET-Fused Tumors

LiFFT
Start date: July 27, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

NCT ID: NCT05876325 Completed - Pediatric Cancer Clinical Trials

Financial and Insurance Assistance- Oncology Financial and Legal Navigation Program

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The overall objective of this study was to develop and evaluate FINassist (Financial and Insurance Navigation Assistance), a patient-centered, interdisciplinary team-based oncology financial and legal navigation program. The program leverages Medical Legal Partnerships to enhance cost of care conversations with pediatric oncology patients and caregivers. FINassist optimizes the team-based care model by integrating clinicians, social workers, financial navigators, and legal advocates who work in tandem to enhance cost of care conversations with patients and caregivers, identify and intervene on patient socio-legal needs, and advocate for system-level changes.

NCT ID: NCT05872893 Recruiting - Pediatric Cancer Clinical Trials

Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone

Start date: June 27, 2023
Phase: Phase 3
Study type: Interventional

Chemotherapy-induced nausea and vomiting are serious side effects of cancer treatment that can have a significant negative impact on a patient's quality of life. Although the prevalence of nausea and vomiting has significantly decreased due to the implementation of new antiemetic drugs, several studies revealed that approximately 30% to 60% of patients still complain of acute or delayed chemotherapy-induced emesis. It is estimated that slow infusion of ondansetron in combination with dexamethasone can provide long-lasting stable concentrations of drugs in the blood serum contributing to better effect development. Therefore, the investigators suggest a continuous infusion of the above-mentioned drug combination as an alternative with potential superior activity.

NCT ID: NCT05851625 Recruiting - Chemotherapy Effect Clinical Trials

Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients

Start date: October 16, 2023
Phase: N/A
Study type: Interventional

Chemotherapy is a cancer therapy performed on advanced cancer with quite good success, but this therapy has quite a lot of side effects. Chemotherapy induced nausea and vomiting or commonly known as CINV, is a condition of nausea and vomiting experienced by cancer patients undergoing chemotherapy, with a prevalence of around 80% of all patients undergoing chemotherapy, and 40% has the potential to become severe. This study aims to determine the efficacy of a new acupuncture modality, namely the press needle, in preventing CINV symptoms in pediatric patients with cancer undergoing chemotherapy. The study was conducted using a randomized controlled clinical trial (RCT) design in 64 pediatric cancer patients undergoing chemotherapy who were randomized into 2 groups, namely: (1) standard medical therapy as the control group; and (2) a combination of standard therapy with press needle acupuncture as the treatment group. The ear acupuncture points used are Shenmen and Stomach, and one body acupuncture point is PC6. Outcome measurements were carried out in the form of the RINVR questionnaire to assess the intensity of nausea and vomiting measured at 4 times: (1) 3 days before chemotherapy; (2) days of chemotherapy; (3) 12 hours after chemotherapy; (4) 3 days after chemotherapy.

NCT ID: NCT05844670 Recruiting - Pediatric Cancer Clinical Trials

CHildren Treated With Vincristine: A Trial Regarding Pharmacokinetics, DNA And Toxicity of Targeted Therapy In Pediatric Oncology Patients.

CHAPATI
Start date: April 20, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to individualize the dosage of vincristine, a chemotherapy drug, in children with cancer. The main question it aims to answer is: can vincristine dosage be optimized while carefully monitoring toxicity. The following will happen: - Participants will receive vincristine according to the institutional treatment protocol. - After receiving vincristine, blood samples will be taken at three time points. - The amount of vincristine in the blood samples will be determined. - If the amount of vincristine in the blood samples is lower than the reference and the participants do not experience toxicity due to vincristine, the dose of vincristine may be increased. - Toxicity will be carefully monitored.

NCT ID: NCT05792566 Recruiting - Pediatric Cancer Clinical Trials

ATOMIC Mobile App to Increase Physical Activity (PA) Levels in Survivors of Childhood Cancer

Start date: June 12, 2023
Phase: N/A
Study type: Interventional

Development and Usability Testing of the ATOMIC Mobile App to Increase Physical Activity (PA) Levels in Children, Adolescent and Young Adults (AYA) survivors of childhood cancer

NCT ID: NCT05783323 Recruiting - Cancer Clinical Trials

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Start date: February 14, 2024
Phase: Phase 2
Study type: Interventional

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.

NCT ID: NCT05783310 Completed - Pediatric Cancer Clinical Trials

Psychoeducation Intervention for Caregivers of Children With Cancer

Start date: May 22, 2023
Phase: N/A
Study type: Interventional

This randomized controlled trial aims to evaluate the effectiveness of the psychoeducation intervention on anxiety, depressive symptoms, coping, and HRQoL in caregivers of children with cancer. The study is a two-arm parallel-group single-blind, randomized controlled trial that will be conducted in two hospitals in Malawi.

NCT ID: NCT05704790 Recruiting - Pediatric Cancer Clinical Trials

Feasibility and Acceptability of Brief, Telehealth Cognitive Compensatory Training for Pediatric Cancer Patients

Start date: February 17, 2023
Phase: N/A
Study type: Interventional

This pilot study will be a prospective, single arm study to investigate the feasibility and acceptability of a brief, telehealth, cognitive compensatory training intervention for children with a history of pediatric cancer at the University of Michigan. Study aims to enroll 10 children with a history of treatment for pediatric cancer, along with their caregiver.